JACOB MANDEL to Disease-Free Survival
This is a "connection" page, showing publications JACOB MANDEL has written about Disease-Free Survival.
Connection Strength
0.134
-
Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. J Neurooncol. 2016 08; 129(1):147-54.
Score: 0.110
-
Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol. 2014 Aug; 119(1):135-40.
Score: 0.024